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1. Introduction 
Hepatic encephalopathy (HE) is a neuropsychiatric condition affecting patients  
with cirrhosis, acute liver failure and portal-systemic bypass1, 2, 3. The neuropsychiatric 
abnormalities include changes in levels of consciousness, behavior, intellect, and neurologic 
exam. The changes in levels of consciousness can range from altered sleep habits to coma. 
HE is a frequent complication in patients with cirrhosis and is broadly classified as minimal 
HE and overt HE. Minimal HE is defined as subclinical cognitive dysfunction, only detected 
by neuropsychiatric testing, and is present in up to 80% of patients with cirrhosis4. Overt HE 
is defined in patients with active HE or a previous episode of HE and is present in 30-45% of 
patients with cirrhosis5.  
HE results from the overproduction or impaired metabolism of one or more neurotoxin. The 
general consensus is that ammonia with inflammation in the serum is believed to be the 
underlying trigger to developing HE. Normally, ammonia enters the portal system from the 
gut. When the liver is unable to clear ammonia, secondary to a limited number of viable 
hepatocytes or portal-systemic shunting, ammonia can enter the systemic circulation and 
enter brain tissue. Elevated ammonia with inflammation can impair normal 
neurotransmission and result in a variety of neuropsychiatric abnormalities6. The 
inflammatory component is usually related to bleeding, dehydration or sepsis4.  
1.1 Classification 
The most common classification used for research purposes is the West Haven Criteria (also 
called Conn Score) (table I-1)8. The West Haven Criteria is graded with a range of 0-4. The 
far ends of the spectrum, grades 0 and 4, have fairly obvious clinical manifestations with no 
abnormalities and comatose, respectively 8, 9. However, the major criticism of the West 
Haven Criteria is deciphering the middle categories, 1-3, which can be difficult to reproduce 
due to the subjectivity involved with the assessment. 
The World Congress of Gastroenterology developed a classification system for HE in 1998 
based on underlying hepatic abnormalities. The three types are A, B, and C and are 
associated with Acute liver failure, portal systemic Bypass without intrinsic liver disease, 
and Cirrhosis, respectively 2, 3, 10. Type C can be subcategorized into persistent, episodic, and 
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minimal HE depending on symptoms and presentation. Persistent HE is subdivided into 
mild, severe, and treatment-dependent. Persistent HE presents with cognitive defects that 
negatively affect social and occupational functioning. The differences between mild and 
severe persistent HE depend on the West Haven Criteria. Mild persistent HE is present 
when a patient has met the persistent HE definition as well as having West Haven grade 
one, whereas severe persistent HE is present with grade two, three, or four of the West 
Haven Criteria. Treatment-dependent persistent HE implies that overt symptoms develop 
when treatment stops10. Episodic HE is subdivided into recurrent, precipitated, and 
spontaneous. Episodic is essentially viewed as delirium secondary to a general medical 
condition, with delirium defined as a disturbance of consciousness that is accompanied by a 
change in cognition that cannot be accounted for by a pre-existing or evolving dementia. 
Recurrent episodic HE is defined as having had two or more episodes in one year. 
Precipitated episodic HE is caused by an identifiable precipitant which led to the HE 
episode. These precipitants are listed in Table P-1. Spontaneous episodic HE is diagnosed 
only if no precipitant can be identified and all other causes of mental status alteration have 
been ruled out. Minimal HE is diagnosed by specialized tests due to the subtlety of its 
presentation. The most commonly used clinical categorization of HE is minimal and overt 
HE. Overt HE includes both persistent and episodic HE. But neither the World Congress of 
Gastroenterology nor the minimal and overt HE Classification systems are scientific or 
precise enough to offer a clear idea of the patient’s clinical condition.  
Due to the inconsistencies between HE severity scores, Bajaj and Cordoba created the 
Spectrum of Neurocognitive Impairment in Cirrhosis (SONIC) to eliminate the phrasing of 
minimal, overt and normal, as well as the scoring system of West Haven Criteria7. In 
utilizing a spectrum, the physician can follow the patient’s mental status on a day-to-day 
basis with standardization in place to allow all providers to understand the clinical course of 
the patient. Although this spectrum was created to eliminate other severity classifications, 
the use of both West Haven Criteria and minimal/overt HE descriptions is widely practiced. 
Other scoring systems have been used in small studies such as the HE Scoring Algorithm 
(HESA)11 and clinical hepatic encephalopathy staging scale (CHESS)162 but they have not 
been tested in large, multicenter trials 7.  
Stage Consciousness Intellect/behavior Neurological findings 
0 Normal Normal Normal exam 
1 Mild lack of 
awareness 
Shortened attention span, 
impaired addition/subtraction 
Mild asterixis or tremor 
2 Lethargic Disoriented; inappropriate 
behavior 
Obvious asterixis; slurred 
speech 
3 Somnolent Gross disorientation; bizarre 
behavior 
Muscular rigidity, clonus, 
hyperreflexia 
4 Coma Coma Decerebrate posturing 
Used with permission from Alimentary Pharmacology and Therapies “Modern management of Hepatic 
Encephalopathy” 2010. 
Table I-1. West Haven Criteria for Hepatic Encephalopathy 
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2. Pathophysiology 
Due to the various etiologies of the liver dysfunction, the etiology of HE is not completely 
understood. Nevertheless, several mechanisms are known to be associated with the 
development of HE and elevated serum ammonia seems to be the spark along with other 
precipitating factors. Precipitating factors can be found in 80% of cases with overt HE12. 
These precipitants work by increasing the underlying inflammatory milieu, or altering the 
ammonia threshold, or a combination of the above. The precipitants are listed in the table 
below (Table P-1). 
Increased 
Nitrogen 
load 
Decreased toxin clearance Altered 
neurotransmission 
Hepatocellular 
damage 
Excess dietary 
protein 
Dehydration Abdominal 
paracentesis 
 
Benzodiazepines Continued 
alcohol abuse 
Constipation Fluid 
restriction 
 
Psychoactive drugs Development of 
hepatocellular 
carcinoma 
GI bleed Diuresis   
Blood 
transfusion 
Diarrhea 
secondary to 
laxatives 
  
Azotemia Hypotension Bleeding   
Vasodilation 
Infection Anemia   
Hypokalemia Portal-systemic shunts   
Table P-1 Common precipitants of hepatic encephalopathy and the underlying mechanisms 
2.1 Ammonia 
The pathophysiology is based largely on the five organs involved in the ammonia 
metabolism – gut, muscles, kidneys, liver, and brain13. The gut, kidneys and muscles are 
involved in the production of ammonia into the blood system. In the gut, ammonia is 
mainly produced by urease producing gut flora, which cleaves protein enzymatically to 
ammonia (NH3), and then absorbed into the portal-system through the colon14. In addition, 
enterocytes contain glutaminase, which converts glutamine to glutamate and ammonia15. 
The kidneys also express glutaminase and are involved in ammonia production during acid-
base balance and dehydration16. With intense exercise or seizure, ammonia is produced in 
the skeletal muscles14.  
Normally, ammonia is metabolized to urea in the liver for renal clearance. Eighty to ninety 
percent of ammonia enters the urea cycle via the liver and is ultimately cleared via the 
kidneys. Ammonia clearance also occurs within the kidneys, skeletal muscles, and brain. 
Ten to twenty percent of ammonia is metabolized by the skeletal muscles and brain via 
glutamine synthetase. Glutamine synthetase is the enzyme responsible for the condensation 
of glutamate and ammonia to form glutamine. In patients with cirrhosis, muscle wasting is 
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common, thus limiting the ability of skeletal muscles to clear ammonia. The kidney expresses 
glutamine synthetase and is capable of increasing ammonia metabolism and excretion17. The 
shunting of blood (physiologic or iatrogenic) away from the liver decreases the ammonia 
metabolism in the liver, and increases systemic circulatory ammonia levels 16, 17.  
In the brain, astrocytes are the only brain cells that can metabolize ammonia into glutamine 
via glutamine synthetase18. Astrocytes have several functions including neurodevelopment, 
maintaining appropriate ion concentrations in extracellular space, and maintaining the 
blood brain barrier and synaptic transmission. They also have the power to regenerate, 
which allows them to aid in repairing neuronal tissue19. When ammonia levels are elevated 
in the brain, glutamine levels are elevated which leads to an influx of water and subsequent 
edema. With chronic exposure to ammonia as well as manganese, astrocytes can undergo a 
morphologic change to Alzheimer type 2 astrocytosis characterized by cell swelling, large 
nuclei, prominent nucleoli, marginated chromatin, and the inability of cells to function20, 21, 
22. The swelling of the astrocytes can cause cerebral edema and intracranial hypertension, 
which leads to global effects on the brain including agitation to seizures14, 23-25. This cerebral 
edema has been demonstrated on MRI by reduced magnetization transfer ratios in patients 
with overt HE 26. The dysfunction of the astrocytes can lead to permanent damage of the 
brain. The permanent neurologic damage was seen in patients who received a liver 
transplant after recurrent episodes of overt HE. The changes included decreased brain 
volume seen on MRI, loss of the N-acetylaspartate/Creatine-phosphocreatine neuronal 
marker, and gross motor dysfunction27. When acute elevation of arterial ammonia to levels 
greater than 200 Umol/L occurs, cerebral autoregulation is lost and cerebral edema and 
intracranial hypertension may result in herniation24, 25. 
2.2 Inflammation 
High levels of ammonia do not cause the symptoms of HE alone; a spark has to be present – 
inflammation. Inflammatory markers are elevated in patients with HE and they can affect 
the liver and neurologic functions. Inflammatory markers were present in a number of 
studies, and they are relevant in the presence of all types of HE. Inflammatory markers 
including C-reactive protein, white blood cell levels, and interleukin-6 are higher in patients 
with minimal HE than those without minimal HE28. In overt HE, cytokines are released by 
the astrocytes in response to ammonia-related injury. Tissue necrosis factor (TNF), which 
arises during inflammation, stimulates more cytokine production as well as altering the 
blood brain barrier (BBB). The permeability of the BBB to ammonia increases with increasing 
severity of liver disease29. Over-active neutrophils have been associated with HE and exhibit 
excessive degranulation and release of reactive oxygen species (ROS). The cytokines 
increase permeability of ammonia to the BBB. Ammonia swells the astrocytes with osmotic 
stress, and oxidative and nitrosative stress may cause apoptosis30. Thus, ammonia and the 
inflammation alter the environment of the astrocytes and BBB in a synergistic fashion to 
create a spectrum of neurologic changes31. 
2.3 Amino acids 
An elevation in aromatic amino acids to branched chain amino acids (BCAA) ratio is present 
in a large portion of patients with cirrhosis and HE. Aromatic amino acids (AAA) are 
elevated relative to baseline in patients with HE. BCAA are utilized more in the presence of 
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hyperammonemia to help in detoxification of ammonia by skeletal muscles. Chronic liver 
disease and portal-systemic shunts are characterized by reduced levels of BCAA32. Aromatic 
amino acids are associated with an altered BBB, due to the transportation of glutamine out 
of the astrocytes which brings AAA into the cells. The imbalance may inhibit normal 
neurotransmitters such as dopamine, serotonin, and norepinephrine 33, 34 or hinder their 
synthesis35. This change in concentration has led to treatment options involving BCAA. 
However, clinical trials of specialized BCAA formulas have yielded mixed results36. 
2.4 Neurologic alterations 
Because of the uncertainty surrounding all of the events in HE, a great deal of substances 
have been observed to be elevated or reduced with HE episodes. GABA, translocator 
protein 18-kDa (TSPO) receptors, endogenous benzodiazepine, glutamate receptors, 
serotonin, catecholamines, melatonin, and histamine, which all have a role in cognitive 
function, have been altered during HE.  
The GABA-benzodiazepine neurotransmitter system has been implicated in HE 
pathogenesis on a number of levels. The GABA receptors were once thought to be a major 
factor in the development of HE; however the receptors have not been shown to be more 
numerous or active in patients with HE. In the clinical setting, patients with liver failure are 
more sensitive to the sedative effects of benzodiazepines than those without liver failure. In 
rat models, ROS and reactive nitrogen species (RNS) are enhanced in the presence of 
benzodiazepines30, 37. Antagonists to GABA-benzodiazepine receptor complex administered 
to rats with mild to severe hepatic encephalopathy produced a transient improvement in 
clinical status38. Neurosteroids, which are metabolites synthesized by cholesterol or steroid 
precursors, have also been associated with the GABA-A receptors. Neurosteroids are 
positive allosteric modulators of GABA-A receptor, thus increasing the GABAergic tone. 
The increased GABAergic tone has been associated with the reduced oxygen requirements 
and subsequent reduced blood flow and metabolism in the brain39. Endogenous 
benzodiazepines, which have also been involved with the activation GABA-Aergic 
neurotransmission, have been identified with contributing to HE. The concentrations of 
these endogenous benzodiazepines have been directly correlated with the severity of HE in 
animal models, but the role in humans has not be completely elucidated40. 
In patients with HE, translocator protein 18-kDa (TSPO) (formerly known as peripheral-type 
benzodiazepine receptor (PTBR)) is upregulated in microglial cells that are activated by 
inflammation41. This receptor is responsible for increasing the neurosteroid concentrations 
that stimulates the GABAergic tone as described above. The TSPO is activated by increases 
in ammonia and manganese40, 42. Ammonia’s presence as an activator of TSPO seems 
appropriate. Manganese has a role as well. Serum manganese levels are not elevated in HE, 
but deposits in the basal ganglia have been seen on MRI. Manganese toxicity has similar 
clinical manifestations as HE, with the addition of Parkinsonian symptoms, which may or 
may not be present in HE21, 22. 
Glutamate receptors have been implicated mainly through the effects of the glutamate, ROS 
and RNS. As part of the “Trojan Horse Hypothesis,” ammonia is thought to induce 
oxidation when produced from glutamine within the mitochondria of astrocytes. The RNA 
oxidation induces N-methyl D-aspartic acid (NMDA) activation43. NMDA receptors are 
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used in the brain function as a means to compartmentalize glutamine and glutamate. Under 
normal conditions, astrocytes support adjacent neurons with ATP, glutamine, and 
cholesterol. The neuron metabolizes glutamine to glutamate, and the NMDA receptors take 
in the glutamate to be recycled back to glutamine. With excess ammonia being metabolized 
to glutamine, the compartmentalization of glutamine and glutamate is altered. Glutamate is 
now in excess, and has been found in the hippocampus and cerebral cortex in patients with 
acute liver failure. Glutamate is an excitatory neurotransmitter, which could lead to 
agitation and possible seizure. In patients chronically exposed to ammonia, these receptors 
are down-regulated, which results in less neuroexcitation from glutamate14, 23-25, 44. 
Meanwhile, glutamine’s concentration increases within the astrocytes and ultimately leads 
to further release of ROS and RNS and swelling. 
Neurochemical alterations have consistently been present in various models of HE. In a 
study by Yurdaydin, the extent of the neurochemical involvement was dependent on the 
severity of the HE. Nevertheless, the study proposed an increase in serotonic and 
noradrenergic neurotransmission in patients with HE40. 
Serotonin is a neurotransmitter involved in the CNS, and it is also a hormone which 
interacts with various other organ systems. Serotonin metabolites are increased in patients 
with HE. In addition, the number of serotonin receptors is altered and catabolizing enzymes 
are elevated40. However, the amount of biologically active serotonin has not been found to 
be elevated. In some studies, it has been reduced in the synaptic clefts45. Despite the 
alterations in the serotonin cycle, the role of serotonin in HE is not clear.  
Catecholamines, particularly altered concentrations of norepinephrine (NE), have been 
implicated in contributing to HE. Catecholamine concentrations are closely linked to the 
AAA:BCAA ratio, thus suggesting a role in amino acid production. BCAA are thought to 
either competitively inhibit catecholamines or hinder their synthesis. NE is typically 
reduced in the brain of rats in acute or chronic liver failure. This reduction in NE would 
result in general slowing of cognitive processes most notably seen in minimal HE or overt 
HE types B and C. The possible cause of reduced levels of NE may also be directly related to 
hyperammonemia. Elevated levels of ammonia could potentially cause an increase in the 
noradrenergic transmission46.  
Melatonin and histamine are both involved in the circadian rhythm, which dictates the sleep-
wake cycle. Histamine levels are elevated in the frontal cortex and central histamine 
concentrations have been linked to the control of arousal in the circadian rhythm47. Melatonin 
levels are altered in patients with liver disease. These changes yield the symptoms of altered 
sleep patterns and insomnia usually reported early in the disease state48. 
2.5 Precipitating factors 
HE is precipitated by an event that impacts the patient’s functioning in the vast majority of 
cases. This event may be an increase in nitrogen, decreased ability to clear toxins, altered 
neurotransmission, or further hepatocellular damage49. The most common precipitating 
factors are sepsis, dehydration (secondary to treatment), and variceal bleeding12. Treating 
the precipitating factor is a pillar in treatment of HE. In the event that a precipitating factor 
cannot be identified, the diagnosis of spontaneous HE should be considered. A table of 
precipitating factors is listed in P-1. 
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A large nitrogen load can precipitate an episode of HE. Excess dietary protein, constipation, 
and hypokalemia are all intake/output related, and can be treated with relative ease. 
Hypokalemia’s effects stem from altering the BBB, and allowing more ammonia to cross. GI 
bleeding can also precipitate an episode of HE. GI bleeding leads to an excess of ammonia in 
the blood by digesting and absorbing proteins from the breakdown of red blood cells in the 
intestines. In addition, GI bleeding leads to the production of ammonia from the kidney 
resulting in hyperammonemia as well as potential hypovolemia17, 50. Blood transfusions can 
be a less obvious cause, but must be considered as a potential precipitating event in HE, 
especially after an acute GI bleed.  
Infection is a common contributor to HE. Infection or sepsis is usually apparent with a 
combination of increased temperature, white blood cell count, heart rate and respiratory 
rate. Cirrhotics are also viewed as functionally immunocompromised, therefore, their risk of 
infection is increased31. Because infection is such a common cause of HE, it is standard of 
care to evaluate all patients with HE with an infection workup including blood and urine 
cultures, chest x-ray, skin exam and diagnostic paracentesis4. 
Decreased toxin clearance is generally associated with hypovolemia (dehydration, 
hypotension, or anemia) and portal-systemic shunting (either iatrogenic or spontaneous). 
Shunting of blood away from the liver bypasses hepatic cells and minimizes the clearance of 
toxins51. Dehydration and anemia, which are usually associated with hypotension, can lead 
to ineffective clearance of toxins by the kidneys. On occasion, hypotension can be due to 
systemic vasodilation which has the same result of ineffective toxin clearance. The lack of 
clearance in all of these processes leads to increased levels of toxins, most notably ammonia. 
As noted in the astrocyte physiology, neurotransmission is vital to neurologic functioning. 
Altered neurotransmission is known to be a precipitating factor in HE. Patients placed on 
benzodiazepines or any psychoactive drug may react drastically for separate, yet related 
reasons. Endogenous benzodiazepines are elevated during HE, and increasing the 
concentration of these would severely affect the patient40. With the hepatocytes damaged 
from the liver disease, blood shunted away from the liver, and various transporter proteins 
downregulated as a result of the liver disease, drugs affecting the cognitive function of a 
patient will have a more pronounced effect including stimulants (caffeine, amphemtamines, 
methylphenidate) and depressants (sedatives, narcotics)52. 
Although hepatocellular damage is already present, in certain situations it can be worsened. 
Continued abuse of alcohol may cause worsening hepatic function, which can lead to a 
spontaneous shunt and a buildup of toxins in the blood and brain. Also, the development of 
hepatocellular carcinoma in the setting of cirrhosis may worsen the patient’s status53. 
3. Diagnosis 
The diagnosis of overt HE is generally made by the presence of clinical signs and symptoms, 
elevated ammonia levels, and the absence of other possible causes of altered mental status. 
The signs and symptoms seen early are alterations in sleeping patterns, which can progress 
to somnolence and on to obtundation48. Some patients may become more agitated usually 
occurring in Type A HE54-56. Types B and C HE presentations are more associated with 
neuroinhibitory symptoms57-59. Nevertheless, the approach to anyone suspected of having 
www.intechopen.com
 
Miscellanea on Encephalopathies – A Second Look 
 
128 
HE is to exclude other possible causes of encephalopathy, identify precipitating factor, and 
empiric treatment for HE. 
Clinical features of overt HE include those associated with consciousness, intellect and 
behavior, and gross neurological findings. In regards to consciousness, the patient can range 
from no impairment or mild lack of awareness to lethargy, somnolence or coma. Intellect 
and behavior changes include shortened attention span, disorientation, and inappropriate or 
bizarre behavior60. Neurological findings on exam include impaired psychomotor testing, 
varying extent of asterixis, slurred speech, rigidity and hyperreflexia, and transient 
posturing61. These signs and symptoms are all recognized by the West Haven Criteria and 
are graded by the severity of HE (Table I-1). 
A detailed physical exam must be performed mainly to rule out other causes of altered 
mental status and to help elucidate possible precipitating factors. The general appearance of 
jaundice signifies underlying liver dysfunction, and often clues the physician as to the 
etiology of the altered mental status. Other evidence of liver failure, such as ascites, palmar 
erythema, edema, spider telangiectasias, muscle wasting and fetor hepaticus, may also be 
present in patients with overt HE62. Monitoring the patient’s vital signs may also help with 
determining the precipitating factor(s) that induced the overt HE. A digital rectal exam 
should also be performed to assess for constipation and fecal occult blood as precipitating 
factors for the HE.  
The neurologic exam is critical to assess the patient’s altered mental status as disorientation 
and that other etiologies of the encephalopathy can be excluded. The alertness and 
orientation are aspects of the neurologic exam that usually separates the various grades of 
HE using the West Haven Criteria, and it is a critical symptom that may determine the need 
for hospitalization (grades 3 and 4). Mental status evaluations should be assessed to exclude 
other causes such as Alzheimers and neurovascular disease as well as to grade the 
encephalopathy according to the West Haven Criteria63. A detailed neurologic exam must be 
performed to rule out a neurologic cause contributing to the change in mental status64. Overt 
HE typically causes a global process, and any focal findings in the neurologic exam must be 
further pursued. Focal findings such as hemiplegia is an extremely rare presentation for 
overt HE. Focal neurologic signs are not prognostic and are usually reversible when 
associated with HE65. Asterixis is a common physical sign associated with overt HE. The 
presence and severity of asterixis can help grade the HE when using the West Haven 
Criteria. The assessment of asterixis requires an outstretched arm with extension of the wrist 
and is positive if a flapping tremor is present66. Alternatively, asterixis can be evaluated 
having the patient grip the evaluator’s fingers in steady fashion and is present if the 
patient’s grip tension oscillates. Parkinsonian-like symptoms may be present in the form of 
rigidity and tremors4. 
Lab values play a vital role in the diagnosis of HE with the close monitoring of the ammonia 
levels. The ammonia level is typically elevated to quantities well above the upper normal 
limits during an episode of HE. The numerical value of the ammonia levels generally 
correlates to the extent of mental status change. However, there is a delay in the resolution 
of symptoms after ammonia levels return to normal, and routine ammonia measurements 
after diagnosis is not recommended63, 67. In the event that ammonia is elevated and no 
underlying liver disease was present, labs should be collected to rule out inborn errors in 
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metabolism (IEM) of urea. The IEM that present in adulthood include ornithine 
transcarbamylase, carbamyl synthetase, and arginosuccinate lyase deficiencies with each 
having measurable enzyme lab values13.  
Other labs should be checked to determine the precipitating factor, which may have 
induced the overt HE. Discovering this factor is vital to the treatment of HE and the ultimate 
resolution of symptoms. For this reason the serum electrolytes must be checked due to the 
precipitating factors of hypernatremia, hypokalemia, hyperglycemia, and hypoglycemia49. 
The white and red blood cell counts should also be checked to evaluate for possibility of 
infection or GI bleed, respectively.  
Obtaining pharmacologic levels of potentially toxic medications should be obtained in 
patients with liver disease receiving multiple drugs and having altered first pass liver 
metabolism. In addition, a urine drug screen may provide answers to patients with altered 
mental status.  
Cultures should be drawn from the blood, urine, and ascitic fluid to evaluate for infection as 
precipitating factor of HE4. A chest x-ray may be necessary to rule out pneumonia. A lumbar 
puncture may be necessary to rule out meningitis. Cultures usually take 24 hours for 
preliminary results and therefore antibiotics should be started empirically if clinical 
suspicion is high for infection. Although infection may induce overt HE, sepsis may present 
with altered mental status with an ammonia level within the normal range63. White blood 
cell count, respiratory rate, heart rate, and temperature should be closely monitored due to 
differing treatments between overt HE and sepsis.  
Radiologic imaging has a minimal role in diagnosing HE. When an unknown patient 
presents with altered mental status or general somnolence, it is appropriate to rule out an 
acute intracranial process with a non-contrast CT of the head. Because many patients with 
liver disease also have coagulopathies and are subject to falls, the head CT is clearly 
warranted. Imaging must be used in these instances when ruling out an intracranial process 
that could either be the etiology of the change in mental status or exacerbating HE68. 
However, in the event of diagnosing HE, radiologic images have not been shown to be 
necessary. Brain MRI’s are increasingly being used to identify low-grade cerebral edema in 
HE, but this is often used for research purposes. As discussed in the sections above, several 
imaging modalities have identified abnormalities used in deciphering the pathophysiology 
of HE. For instance, magnetic transfer ratio was reduced in patients with HE, but reverses 
with liver transplantation. This finding suggests that the metabolic effects of HE maybe 
reversible69. T1-weighted imaging showed manganese in the basal ganglia suggesting a role 
of manganese in the pathophysiology of HE70-72. Proton spectroscopy (MRS) is mentioned as 
the evidence of glutamate involvement within the astrocytes during HE59.  
Although radiologic imaging has a minimal role in diagnosis and treatment, several 
modalities may be seen in the future for staging liver disease and the severity of HE. MRS 
changes directly correlate with severity of HE. This correlation could be used in the staging 
of liver disease as an illustrative way of monitoring the toll the disease is having on the 
brain. Although its variability and costs prevent it from being used routinely today, future 
management of chronic liver disease may include MRS73. T1 mapping with partial inversion 
recovery (TAPIR) is another method that correlates changes with HE severity. This method 
maps the brain through a series of T1 MRI scans. Unlike MRS, TAPIR offers measurements 
in short, clinically relevant acquisition times74.  
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Electroencephalography (EEG) is a tool used primarily in the research setting for diagnosis 
of HE. HE is associated with a decrease in mean frequency of electrical activity in the brain 
in the spectral EEG. Triphasic waves are noted in advanced HE75. However, EEG readings 
have demonstrated subjectivity, and the test has a low sensitivity. Furthermore, the 
equipment is expensive and the test has not been validated76, 77. 
3.1 Specialized tests 
Specialized tests have been developed to quantify the degree of HE and also to monitor 
recovery or progression. Minimal HE is not diagnosed clinically, but it is diagnosed with 
neuropsychometric (NP) tests. These tests are useful tools in assessing progression of minimal 
HE as well as the initial diagnosis by identifying impairments in visuospatial functioning, 
attention, processing speed and response inhibition4, 78. Minimal HE does not have a gold 
standard for diagnosis or assessment through neuropsychometric testing. Two tests, 
Psychometric HE Score (PHES) and Repeated Battery for the Assessment of 
Neuropsychological status (RBANS), are recognized by prominent organizations worldwide, 
although no single test has gained significant popularity or validation in the US62. 
Psychometic HE Score (PHES) (also referred to as the PSE Syndrome Test) consists of a 
battery of five tests; Number connection tests (NCT)-A, NCT-B, line tracing test, serial 
dotting tests and digit symbol test. The diagnosis of minimal HE is made if any two of the 
NP tests are impaired beyond two standard deviations from normal64. The whole test 
requires an educated instructor, paper, and pencil. The PHES typically requires 10-20 
minutes to complete75. The PHES was recognized by the World Congress of 
Gastroenterology in 1998 and is validated in Germany, Italy, and Spain. The Working Group 
of Hepatic Encephalopathy has recommended the PHES, but validation of this test has yet to 
be completed in the United States (US)79-81. 
The Repeated Battery for the Assessment of Neuropsychological status (RBANS) is a test 
similar to PHES with the addition of verbal, visual, and working memory domains. The test 
requires 20-25 minutes to complete, and is administered by paper and pencil. RBANS was 
created to gauge Alzheimer’s Disease, schizophrenia, traumatic brain injury, and in some 
patients with cirrhosis awaiting liver transplantation. The International Society for the Study 
of HE and Nitrogen Metabolism (ISHEN) has recommended this test for diagnosis of 
minimal HE along with PHES. A modified version of RBANS is used in the US for overt HE, 
and has been proven to be effective in screening patients for minimal HE82-84. The RBANS 
recommended by ISHEN is currently being validated in the US in a multicenter trial85, 86. 
Performing the PHES or the RBANS require supervision by a neurologist, specialized 
equipment, trained personnel, and time. These tests rely on motor activity, which are often 
limited in patients with HE by the West Haven Criteria grades 2 to 4. Thus additional 
testing of HE has been used. The Critical Flicker Frequency (CFF) is a test of functional 
efficacy of the cortex, and it is a highly objective and sensitive measure of minimal HE. This 
test consists of a patient indicating the minimum frequency at which a flickering light is still 
perceived as flickering and not fused. In Spain and India, it has been effective in 
differentiating minimal HE or early stage HE from no HE87, 88. It positively correlates with 
NP tests, and it is not influenced by gender, education level, occupation, and only slightly 
by age. It was validated for assessment of patients with HE in 2002 and for patients with HE 
who were undergoing TIPS placement in 200966, 89. For patients with reduced motor skill 
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function undergoing HE assessment, pressing a button instead of performing a detailed 
pencil and paper test is more appropriate. Reaction times are directly measured and should 
increase the accuracy of assessing HE85.  
Computerized psychometric tests are gaining popularity and could revolutionize the 
assessment of patients with HE78. The inhibitory control test is the most popular in the US. 
Its focus is primarily on response inhibition and attention. It has shown close correlations 
with other NP tests, but investigations have been limited to only Wisconsin and Virginia, 
USA. The inhibitory control test offers promise in that training of the technician is minimal, 
and the cost of the test may be cheaper than the NP tests. Furthermore, the inhibitory 
control test can also predict overt HE, and it is associated with driver simulator performance 
and traffic accidents in the US87, 90, 91. Cognitive Drug Research Ltd computerized assessment 
system was designed specifically for cirrhosis and minimal HE, and it focuses on power of 
attention, continuity of attention, quality of episodic memory, quality of continuous 
memory and speed of memory. This test is popular in the UK and has shown good 
correlation with PHES92.  
4. Treatment 
Treatment of overt HE is based on a multifaceted approach of reducing the ammonia levels, 
treating the precipitating factor, and evaluating the patient for liver transplantation. After 
the overt HE resolves, the focus of therapy shifts to preventing recurrent HE, improving 
daily functioning and quality of life, and continuing evaluation for liver transplantation. 
Therapies can be viewed as short-term treatments, long-term treatments, and sometimes 
they can be used in both circumstances. 
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Diagram T-1. Treatment of Hepatic Encephalopathy 
Patient safety is another important aspect of therapy. Patients with Type A HE are typically 
more agitated, and they pose greater risk to hurt themselves, family, and staff. For this 
reason and because of the possible effects of sedatives, judicious use of restraints is 
recommended. Haloperidol is a safer sedative than benzodiazepines most likely due to the 
endogenous benzodiazepines or increased benzodiazepine receptors produced in HE and 
liver disease. However, there is little evidence to support haloperidol’s use in sedation of 
patients with HE93.  
For patients with minimal HE, treatment is focused on family and patient discussions of 
potential complications that can develop as patients transition to overt HE and to discuss 
limitations in activities of daily living. In particular, several studies have shown the effect 
that minimal HE has on the patient’s driving performance. One study showed patients with 
cirrhosis and minimal HE were involved in 17% of crashes compared to cirrhosis without 
minimal HE 0%91. It should be noted that patients often overestimate their fitness to drive94. 
Patients and their family members must be aware that limiting or revoking the patient’s 
drivers’ license may be necessary.  
Once overt HE has been diagnosed, the clinician must search for precipitating factor(s). 
Once the precipitating factor(s) has been identified, treatment must be directed to resolve 
the offending agent. It is also important to identify the precipitating factor to prevent 
recurrence. While treating the precipitating factor will resolve the primary mechanism 
responsible for the overt HE, reducing the ammonia will help alleviate the cognitive 
dysfunction.  
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4.1 Ammonia treatments 
Lactulose is a synthetic non-absorbable dissacharide which is used as a cathartic to help 
clear ammonia through bowel movements. Lactulose also lowers the pH in the colon by 
being catabolized to lactic and acetic acid, which reduces ammonia levels in two additional 
ways. A lower pH will facilitate the conversion of ammonia (NH3) to ammonium (NH4+), 
which is poorly absorbed across the colon95. A lower pH also makes the environment more 
unfit for urease-positive bacteria, which decreases production of ammonia96-98. Lactulose has 
been shown in numerous studies to be effective, and when used appropriately it is as 
effective as any new medications. Dosage and administration depends on grade of HE and 
goal of therapy. For overt HE (grades 1-2), recommendations is to start lactulose orally with 
20 g/30 ml every 1-2 hours until patient has 2-4 soft bowel movements. The dosage should 
always be titrated so that the patient has 2-4 semisoft bowel movements each day2, 61. If the 
HE grade is ≥ 3, lactulose should be administered via enema due to risk of aspiration. The 
starting enema dosage is 200 gm/300 ml with 700 ml water or saline every 4 hours titrated. 
Although lactulose has been proven to be more effective than placebo in treating HE, the use 
of lactulose has not been proven to reduce mortality99. 
Lactulose can also be used in the long-term treatment of patients with chronic liver diseases 
to prevent recurrence of HE and in the treatment of minimal HE100. With proper adherence, 
lactulose’s effectiveness has been proven in multiple studies for long-term prevention of 
recurrent HE. Being inexpensive and effective makes lactulose a 1st line agent for both short- 
and long-term therapy 61, 101. 
Diarrhea, abdominal pains, and fatigue are the most common side effects associated with 
lactulose. The side effects can be severe enough that patients discontinue using the 
medication. This discontinuation has been well chronicled in various trials102. The side 
effects of diarrhea can be severe enough that the overuse of lactulose itself could lead to 
hypovolemia or an electrolyte imbalance that induces a new episode of overt HE103. In a 
lactulose adherence trial conducted, nearly half of the patients with recurrent HE were non-
adherent or had ≥ 5 bowel movements which contributed to the development of overt HE 
102. Adherence has been reported as low as 31% in patients prescribed lactulose104. 
Adherence is low due to a lesser quality of life secondary to the side effects of lactulose. 
Patients on lactulose should be closely monitored, as adherence is affected by presence of 
adverse events, lack of insight into disease, inability to self-titrate, consequences of non-
adherence not fully explained, and absence of close follow-up102. 
Lacitol has a similar mechanism to Lactulose, but it is unavailable in the US. It is frequently 
used in England with success similar to lactulose and better adherence. The better adherence 
is due to its superior palatability and less gastrointestinal side effects that are associated 
with lactulose103. Lacitol was also found to have a faster clinical response than lactulose104. 
The US Food and Drug Administration (FDA) approved rifaximin in 2010 for the treatment 
of HE in liver disease. Over 90% of the patients in the registration trial were also receiving 
lactulose. While lactulose’s effects are limited by the adverse side effects, rifaximin has 
minimal side effects. Rifaximin is an antibiotic taken orally with minimal systemic 
absorption107. Its antibiotic properties are thus limited to the gastrointestinal tract, where 
antibiotic coverage includes gram-positive and gram-negative bacteria, although it has 
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minimal effects on gut normal flora108. A review comparing rifaximin to lactulose concluded 
that rifaximin is equally effective and in some studies superior to nonabsorbable 
disaccharides and other antimicrobials in relieving the signs and symptoms observed in 
cirrhotic patients with mild-to-moderately severe HE109. However, due to the lack of side 
effects associated with rifaximin, patient adherence and satisfaction are significantly greater 
in rifaximin110, 111, 112, 113. When factoring in patient adherence to the comparison of lactulose 
and rifaximin, rifaximin is superior.  
Patient’s adherence to rifaximin make it a more practical option for long-term therapy than 
lactulose, however, the cost of rifaximin is substantially higher (approximately 40 dollars a 
day) than that of lactulose (approximately 40-100 dollars a month)114. Thus, rifaximin and 
lactulose compare beyond the medical and physical aspects, they also must be compared in 
the psychosocial realm. A single center retrospective chart review comparing rifaximin to 
lactulose found that patients on rifaximin therapy were less likely to be hospitalized for 
recurrent HE, HE severity was reduced, and hospital stay was shorter than patients on 
lactulose110. These results suggest that rifaximin may be more cost effective in the long run, 
due to less expense associated with hospitalizations. However, multi-center prospective 
studies are lacking to support this claim. Two cost effective analyses reviewing different 
strategies in HE management, found that initial therapy of lactulose monotherapy with 
cross over to rifaximin was the best treatment. In other words, if the patient was intolerant 
to lactulose or responded poorly, then rifaximin was administered107, 115. 
Rifaximin administration has been the subject of debate. In Italy, pulse therapies with 
rifaximin achieved therapeutic effect without developing resistance or clostridium difficile 
infection116. Currently in the US, continuous therapy of 550 mg bid for HE is most widely 
accepted. Although rifaximin’s effects were suffice to warrant US FDA approval, studies 
must continue to investigate maximizing the drug’s benefits.  
Neomycin is another antibiotic that has been approved in the treatment of overt HE. Trials 
with neomycin have not yielded the same results as rifaximin or lactulose. In fact, in a 
randomized study, neomycin was shown to be no better than placebo in 39 patients with 
HE117. In addition, the potential side effects of ototoxicity and nephrotoxicity that can occur 
with systemic absorption has limited its use clinically for treating HE118, 103. 
Metronidazole has been used for the treatment of HE, but has not been approved by the US 
FDA. Small single center studies suggest it may have some benefit in treating HE119. 
However, the major long-term side effect of neurotoxicity, limits its routine use for the 
management of HE103. 
Ornithine-aspartate is a substrate that is used in the urea cycle to convert ammonia to urea 
and glutamine in both hepatic and muscular metabolism. It has been shown in several 
controlled trials to lower ammonia concentrations and provide improvements of mental 
status and cognitive function in patients with mild to moderate HE120 - 122. In a double-
blinded randomized placebo-controlled trial treating patients with acute liver failure, 
ornithine-aspartate did not lower serum ammonia levels or improved survival123. Fifty 
percent of patients report side effects of mild gastrointestinal disturbance, but no major side 
effects have been reported121 - 123. Most trials administered ornithine-aspartate 18-30 g IV 
daily for 1-2 weeks. Additional studies are required before this agent can be recommended 
in the treatment of HE.  
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Sodium benzoate/sodium phenylacetate has been shown to enhance tissue metabolism of 
ammonia. Benzoate interacts with glycine to form hippurate, which is renally excreted. 
Phenylacetate conjugates with glutamine to form phenylacetylglutamine, which is renally 
excreted as well. Both hippurate and phenylacetylglutamine contain nitrogen from 
ammonia. In a prospective, randomized, double-blind study on 74 patients with overt HE, 
an oral dose of 5 grams of sodium benzoate twice daily and lactulose were similar in 
symptomatic improvement as well as adverse effects124. Adverse effects included unpleasant 
taste, nausea, and salt overload. A combination of sodium benzoate and sodium 
phenylacetate intravenously is US FDA approved for the treatment of hyperammonemia in 
urea cycle defects, however, it has not been rigorously studied for HE treatment125, 126. 
Acarbose is an inhibitor of α-glycosidase, which inhibits the conversion of carbohydrates 
into monosaccharides for diabetic patients. It also facilitates the reduction of proteolytic 
bacteria flora that produce ammonia. In a single center randomized control trial comparing 
acarbose at dosage of 150 to 300 mg/day versus placebo in diabetic patients noted serum 
ammonia levels were significantly reduced and symptomatic improvement of HE were 
seen127. This drug is not routinely used for the management of HE due to the product 
information sheet stating acarbose is contraindicated in patients with cirrhosis. 
Dietary protein restrictions were once thought to be necessary in the treatment of HE to help 
resolve hyperammonemia. After many studies were undertaken to examine this belief, it is 
now recommended that dietary protein should remain constant during an overt HE episode. 
The prevalence of malnutrition in cirrhotic patients is estimated to be 65-100%128, 129. Muscle 
wasting is also common in patients with cirrhosis, thus severely limiting ammonia removal 
from skeletal muscles. Protein intake, therefore, should remain constant during any episode 
of HE. The suggested protein requirement of 1-1.5 gram/kg per day for patients with liver 
cirrhosis should be continued during an episode of HE130. 
Probiotics are thought to work by introducing bacteria that do not produce urease. 
Probiotics have been associated with reduced serum ammonia concentrations116. Single 
center studies have demonstrated that probiotics improved cognitive function in patients 
with minimal HE131. A meta-analysis of prebiotics, probiotics, and synbiotics in minimal HE 
showed clinical improvement of minimal HE, but not as great as lactulose132. Probiotics and 
symbiotics were associated with fewer side effects compared to lactulose. While treatment 
options for HE with prebiotics, probiotics, and symbiotics are still being investigated, many 
clinicians are reluctant to introduce live bacteria to functionally immunosuppressed 
patients. 
4.2 Neurotransmission  
BCAA are decreased and AAA are increased in patients with cirrhosis and HE. As 
mentioned in the pathophysiology section, this imbalance inhibits production of 
catecholamines. Restoring balance would seem like a logical treatment, but trials have 
shown inconsistent results. Perhaps the greatest benefit of BCAA therapy is in the ability to 
increase protein intake without compromising cerebral function133. It has been associated 
with increased serum albumin levels as well as improved cellular metabolism in cirrhotic 
patients134. 
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Timing of BCAA therapy may be a crucial factor in its efficacy. In a small study of 12 
patients with cirrhosis, nocturnal administration was associated with increased serum 
albumin levels at three months while daytime administration was not. It is speculated that 
these amino acids are used as calories during the day and protein synthesis when infused at 
night135.  
Two meta-analyses have produced conflicting results. A meta-analysis of 5 clinical trials 
suggested that long-term supplementation of oral BCAA was associated with significant 
improvement in mental recovery from HE and improvement from chronic HE136. However, 
a recent meta-analysis of 11 trials found no convincing evidence that BCAA 
supplementation is beneficial137. Thus, if protein replacement is clinically indicated, BCAA 
supplementation may help with the patient recovery through the increase in protein 
synthesis. 
Flumazenil is the short-acting benzodiazepine receptor antagonist, and has been studied for 
treating patients with HE. Most studies have reported limited success with flumazenil in 
short-term improvement in mental status. In a systematic review, flumazenil was associated 
with a significant symptomatic improvement in patients with HE when compared to 
placebo138. However, clinical improvements are short-term since flumazenil is given 
intravenously and has a half-life of less than an hour138. In addition, caution is advised in 
patients with hepatic impairment and side effects are significant (seizure, nausea and 
agitation) limiting its use clinically49. 
Because the pathogenesis of HE may involve dopaminergic neurotransmission, 
bromocriptine has been studied as a possible treatment option. Bromocriptine stimulates 
dopamine receptors and is approved for Parkinson’s disease treatment. In a small 
randomized study, bromocriptine was no more effective than placebo in resolution of HE. 
However, when bromocriptine was added to more conventional therapies, improvement of 
extrapyramidal symptoms was reported139. Bromocriptine at 30 mg orally twice daily can be 
considered in patients who are refractory to other therapies with extrapyramidal 
symptoms64. 
Zinc deficiency is common among patients with cirrhosis and HE. Zinc is a cofactor of urea 
cycle enzymes140. Zinc supplementation is thought to decrease serum ammonia and GABA 
and norepinephrine in the brain, but studies have shown conflicting results. In a blinded 
study of short-term zinc supplementation in patients with HE, no clinically significant 
benefit was associated with the zinc supplementation141. However, in a study evaluating 
supplementation for 3 months resulted in an improvement of HE142. Zinc toxicity is a 
concern as well as the adverse effects including nausea, vomiting, loss of appetite, 
abdominal cramps, diarrhea, and headaches49. 
4.3 Surgery 
Shunting of blood away from the liver through a portal-systemic shunt predisposes the 
patient to recurrent and persistent HE in patients with cirrhosis, surgical shunts, or TIPS 
placements. Shunting blood away from the liver, limits metabolism of ammonia by the liver. 
A majority of cirrhotic patients with HE is secondary to portal-systemic shunts and not 
hepatocellular dysfunction143. Obliteration of large spontaneous portal-systemic 
anastomoses, surgical shunts, or TIPS can be a therapeutic option among persistent HE 
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patients49. As with any surgical procedure in a patient with cirrhosis, the risk of bleeding 
and hepatic decompensation must be considered when weighing this treatment option. 
The ultimate surgical treatment of HE and liver disease is liver transplantation. Liver 
transplant recipients rarely present with additional HE episodes. HE episodes before liver 
transplantation has been associated with increased morbidity and worse patient functioning 
after transplantation69. For this reason, a patient experiencing his first overt HE should be 
referred to a liver transplant center1. The model for end-stage liver disease (MELD) is the 
scoring system used to list patients with cirrhosis in the US. The clinical data for calculating 
the MELD score includes objective data (serum creatinine, serum total bilirubin, and 
international normalized ratio of prothrombin time), but does not include any subjective 
data, such as episodes of HE or ascites. It has been shown that overt HE worsens prognosis 
over and above the MELD score and results in poorer survival rate with higher grades of HE 
for patients admitted to a hospital144. This further emphasizes the necessity of beginning the 
liver transplant workup following the first episode of overt HE. 
4.4 Dialysis 
Peritoneal dialysis, hemodialysis, continuous venovenous hemofiltration and continuous 
arteriovenous hemodiafiltration have the ability to remove ammonia directly146-151. These 
therapies have proven to be effective in children and adults with urea cycle defects. They 
could serve as a bridge for adults with fulminant hepatic failure while they are awaiting 
liver transplantation.  
4.5 Future/experimental therapies 
Hypothermia is a popular treatment modality for patients who are comatose after a cardiac 
arrest. In patients with HE, the benefits of hypothermia are associated with the reduction of 
free radical production, astrocyte swelling, and inflammation152. This improves cerebral 
blood flow and autoregulation, which reduces potential of intracranial hypertension. It also 
slows the ammonia production in both the gut from urease-positive bacteria and in the 
kidney. Hypothermia has also been shown to slow protein catabolism and prevents the 
neutrophil dysfunction153, 154. Based on all of these mechanisms for clinical improvement, 
hypothermia could be a valuable tool in liver failure and grade 3-4 HE, but large 
randomized trials are needed before routine clinical use31.  
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) used in rheumatic disease 
and other inflammatory processes. The role of indomethacin in HE is to reduce 
inflammation and reduce cerebral blood flow, thus decreasing intracranial hypertension24, 99, 
155. There is excitement surrounding TLR-2, TLR-4, and TLR-9 inhibitors which would 
down-regulate neutrophil activation and therefore inflammation31. The side effect of 
indomethacin and other NSAIDs causing renal failure in cirrhotic patients may limit its use.  
Levocarnitine is a metabolite of lysine degradation and serves as a carrier for short-chain 
fatty acids across mitochondrial membrane. It has been shown to stimulate the urea cycle 
and a delayed onset of HE in hyperammonemic mice, which is thought to be protective 
against ammonia neurotoxicity156. In the two studies conducted on patients with HE, 
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levocarnitine reduced ammonia levels and improved mental status in one, while it provided 
no significant benefit in the other157, 158. Future studies are needed before clinical use.  
The glutamatergic neurotransmitter system has been implicated in the pathogenesis of HE 
in several models. Memantine is an NMDA receptor antagonist, which is hypothesized to 
help reduce the overactivity of NMDA receptors. It is currently approved for the treatment 
of Alzheimer’s Disease. In rats with hyperammonemia and neurologic symptoms, 
memantine administration improved HE grade and neurologic symptoms159. The human 
studies investigating memantine are pending. 
The Molecular Adsorbent Recirculating System (MARS) is an albumin dialysis system that 
allows the removal of protein-bound and water-soluble toxins. A US multicenter 
randomized clinical trial in 70 patients with cirrhosis and grade III and IV HE showed 
significant benefit of MARS versus standard therapy with regard to time to improvement of 
HE160. However, there is no extracorporeal albumin dialysis approved by the US FDA for 
the treatment of HE.  
Spherical Carbon Adsorbent (AST-120) when given orally acts as a sink for neurotoxins and 
hepatotoxins in the gut. AST-120 has been study in rats with cirrhosis and have shown 
decreased arterial ammonia levels, normalization of brain water content and normalization 
of locomotor activity161. Clinical trials are being conducted in humans.  
5. Summary 
The development of HE is a severely debilitating event for patients. Overt HE is a socially 
isolating event for patients, preventing them from working, driving a car and performing 
activities of daily living. Elevated serum ammonia with inflammation in the serum has been 
implicated as the underlying trigger to developing HE. The diagnosis should be considered 
in any patient with underlying liver disease who present with mental status changes and 
asterixis. After a thorough workup to rule out any acute neurologic cause of the patient’s 
condition, a major effort must be made to find the precipitating factor which induced the 
current overt HE. Knowing the precipitating factor will allow both aspects of the HE to be 
treated – the cause and the effect. Treatments should start by eliminating the precipitating 
factor, which will ultimately improve the patient’s condition. Standard treatments are 
focused on the prevention of additional ammonia from entering the blood system. Lactulose 
is a cheap and effective medication that has been studied extensively and it has been proven 
to be as effective as any medication on the market. Rifaximin is another effective medication, 
with minimal side effects. However, these agents do not resolve HE completely, but only 
minimize the number of severe episodes and partially improve mental function in the 
persistent cases of overt HE. Other potential treatments have shown some clinical benefits in 
the treatment of HE and can be considered as third line agents (zinc and sodium benzoate).  
Several therapies are currently being studied, and they offer hope to those who currently 
suffering from recurrent HE. As these therapies become available, the treatment and 
prevention of HE will become easier to both patients and physicians. Until then, liver 
transplantation offers resolution of liver failure and HE, improves patient survival, 
improves quality of life, and decreases healthcare costs. 
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Line Agent Dosage Side effects 
First lactulose Acute -- enemas: 300 ml in 1000 ml 
every 2 hour until clinical 
improvement . 
Abdominal 
cramps, 
diarrhea, 
dehydration Acute -- oral: 45 ml each hour until 
bowel movement and clinical 
improvement 
Chronic -- oral: 15-45 ml tid or bid 
continuous until 2 to 3 bowel 
movements per day. 
Second Rifaximin Chronic -- oral: 400-550 mg po bid Flatulence 
Second Neomycin Acute -- oral: 1 g every 6 hours for 
up to 6 days 
Ototoxicity, 
nephrotoxicity  
Chronic -- oral: 1-2 g/day 
Second metronidazole Chronic -- oral: 250 mg bid Neurotoxicity 
Third Sodium 
benzoate/sodium 
phenylacetate 
Chronic -- oral: titrate up to clinical 
improvement or a maximum dose 
of 5 g bid 
Emesis 
Third Zinc acetate, Zinc 
gluconate, zinc 
sulfate 
Chronic -- oral: 11 mg in adult 
males and 8 mg in adult females 
every day 
Nausea 
Third  bromocriptine Chronic -- oral: 30 mg bid Nausea, 
hypotension, 
headache, 
dizziness 
Fourth Surgical Chronic -- surgical obliteration of 
large spontaneous portal-systemic 
anatomoses 
Bleeding, 
infection 
Table S-1. Treatment Summary 
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